NASDAQ: NXTCNextcure Inc Stock
$1.74+0.06 (+3.57%)
Updated Jun 2, 2023
NXTC Price
$1.74
Fair Value Price
$2.70
Market Cap
$48.43M
52 Week Low
$1.16
52 Week High
$5.27
P/E
-0.69x
P/B
0.31x
P/S
N/A
PEG
N/A
Dividend Yield
N/A
Revenue
$0.00
Earnings
-$70.23M
Gross Margin
N/A
Operating Margin
N/A
Profit Margin
N/A
Debt to Equity
0.09
Operating Cash Flow
-$53M
Beta
0.96
Next Earnings
Aug 2, 2023
Ex-Dividend
N/A
Next Dividend
N/A
NXTC Overview
NextCure, Inc., a clinical-stage biopharmaceutical company, engages in discovering and developing novel immunomedicines to treat cancer and other immune-related diseases by restoring normal immune function. Its lead product candidate is NC318, which is in Phase II clinical trials for the treatment of advanced or metastatic solid tumors. The company is also developing NC410, which is in Phase I for novel immunomedicine designed to block immune suppression mediated by an immune modulator called Leukocyte-Associated Immunoglobulin-like Receptor 1; NC762, an immunomedicine targeting a molecule called human B7 homolog 4 protein, or B7-H4; and NC525, a novel LAIR-1 antibody which is in Preclinical trails that targets acute myeloid leukemia, blast cells, and leukemic stem cells. Its discovery and research programs include an antibody in preclinical evaluation of other potential novel immunomodulatory molecules. The company has a license agreement with Yale University. NextCure, Inc. was incorporated in 2015 and is headquartered in Beltsville, Maryland.
Zen Score
–
Industry Average (26)
You've viewed Zen Score for 10/10 free stocks. Upgrade to Premium to see how NXTC scored across 33 valuation, financial, forecast, performance, and dividend due diligence checks.
Due Diligence Checks
NXTC ($1.74) is undervalued by 35.55% relative to our estimate of its Fair Value price of $2.70 based on Discounted Cash Flow (DCF) modelling, but does not have a significant margin of safety
Below Fair Value Valuation
NXTC ($1.74) is significantly undervalued by 35.55% relative to our estimate of its Fair Value price of $2.70 based on Discounted Cash Flow (DCF) modelling, which includes a healthy margin of safety
Significantly Below Fair Value Valuation
NXTC is unprofitable, so we... subscribe to Premium to read more.
Below Benjamin Graham Formula Value Valuation
There are 30 more NXTC due diligence checks available for Premium users.
Be the first to know about important NXTC news, forecast changes, insider trades & much more!
NXTC News
Valuation
NXTC fair value
Fair Value of NXTC stock based on Discounted Cash Flow (DCF)
Price
$1.74
Fair Value
$2.70
Undervalued by
35.55%
NXTC ($1.74) is undervalued by... subscribe to Premium to read more.
Below Fair Value Valuation
NXTC ($1.74) is significantly undervalued... subscribe to Premium to read more.
Significantly Below Fair Value Valuation
NXTC is unprofitable, so we... subscribe to Premium to read more.
Below Benjamin Graham Formula Value Valuation
NXTC price to earnings (PE)
For valuing profitable companies with steady earnings
Company
-0.69x
Industry
11.51x
Market
52.69x
NXTC price to book (PB)
For valuing companies that are loss-making or have lots of physical asset
Company
0.31x
Industry
5.2x
NXTC is good value based... subscribe to Premium to read more.
P/B vs Industry Valuation
NXTC's financial health
Profit margin
Revenue
$0.0
Net Income
-$16.1M
Profit Margin
0%
NXTC's cash and short-term investments... subscribe to Premium to read more.
Interest Coverage Financials
Assets to liabilities
Assets
$167.8M
Liabilities
$13.6M
Debt to equity
0.09
NXTC's short-term assets ($148.92M) exceed... subscribe to Premium to read more.
Short-term Liabilities Financials
NXTC's short-term assets ($148.92M) exceed... subscribe to Premium to read more.
Long-term Liabilities Financials
NXTC's debt to equity ratio... subscribe to Premium to read more.
Healthy Debt to Equity Financials
Cash flow
Operating
-$14.8M
Investing
$18.1M
Financing
$0.0
NXTC's cash and short-term investments... subscribe to Premium to read more.
Debt Coverage Financials
NXTC vs Biotech Stocks
Nextcure Stock FAQ
©2023 WallStreetZen
Company
AboutBlogStock Investing FAQPlansPrivacy PolicyTerms of ServiceCancellation & RefundsHelp GuidesContactTwitterYouTubeWallStreetZen does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.
Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.
Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.